Clinical Trials Browser

Phase 4 × Imatinib Mesylate × Clear all

NCT01742299 2026-04-01

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

Phase 4 Active not recruiting

155 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04877522 2026-03-06

Asciminib Roll-over Study

Phase 4 Recruiting

347 enrolled

MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05071482 2025-05-01

Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

Phase 4 Terminated

39 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03844360 2025-03-30

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Phase 4 Recruiting

1,500 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT05367765 2022-05-10

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Phase 4 Not yet recruiting

2,400 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02602314 2022-01-20

SUSTRENIM

Phase 4 Unknown

450 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00510354 2020-09-10

Radix

Phase 4 Completed

28 enrolled

GastrointestinalSarcoma

Progressive Gastrointestinal Stromal Tumor

NCT01578213 2019-12-03

ISAV

Phase 4 Completed

112 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02204722 2018-06-15

IDEAL

Phase 4 Terminated

55 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00171899 2017-02-23

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Phase 4 Completed

80 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00372476 2017-02-07

INV181

Phase 4 Completed

33 enrolled

Breast

Breast Neoplasms

NCT00845221 2016-10-11

Glivec in Pediatric Chronic Myeloid Leukemia (CML)

Phase 4 Completed

44 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02894645 2016-09-30

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Phase 4 Unknown

500 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01297777 2016-08-29

Imatinib in KIT-negative Systemic Mastocytosis

Phase 4 Completed

10 enrolled

Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

NCT02317159 2014-12-15

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Phase 4 Unknown

90 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00171977 2012-08-07

Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)

Phase 4 Completed

64 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00081926 2009-11-23

Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Phase 4 Completed

112 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00390897 2008-11-27

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

Phase 4 Completed

360 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive